INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, has announced it has entered into a know-how collaboration agreement with Mayo Clinic. The collaboration seeks to accelerate the development and commercialization of INBRAIN’s precision BCI-Tx for patients with unmet needs in neurological-related disorders.
As part of the collaboration, INBRAIN and Mayo Clinic experts will work together on a non-exclusive know-how exchange to engage in hands-on evaluation of INBRAIN’s investigational BCI-Tx platform in IRB-approved settings with the goal of accelerating, high-quality evidence generation.
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, has announced it has entered into a know-how collaboration agreement with Mayo Clinic. The collaboration seeks to accelerate the development and commercialization of INBRAIN’s precision BCI-Tx for patients with unmet needs in neurological-related disorders.As part of the collaboration, INBRAIN and Mayo Clinic experts will work together on a non-exclusive know-how exchange to engage in hands-on evaluation of INBRAIN’s investigational BCI-Tx platform in IRB-approved settings with the goal of accelerating, high-quality evidence generation.
Read More Graphene-Info – Graphene industry portal














